Chinese Journal of Pharmacovigilance ›› 2020, Vol. 17 ›› Issue (6): 342-347.
DOI: 10.19803/j.1672-8629.2020.06.05

Previous Articles     Next Articles

Antiplatelet Aggregation Effect of Vanillic Acid In Vitro and In Vivo

KONG Linglei1, WANG Haigang1, LIU Chengdi1, ZHANG Sen1, LIU Nannan1,2, MA Guodong1, DU Guanhua1*   

  1. 1 Beijing Key Laboratory of Drug Target and Screening Research, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
    2 Guangdong Pharmaceutical University, Guangzhou Guangdong 510006, China
  • Received:2020-03-24 Revised:2020-06-22 Online:2020-06-15 Published:2020-06-01

Abstract: Objective To evaluate systematically in vivo and in vitro the anti-platelet aggregation effect of vanillic acid (VAA), which is a phenolic compound with antioxidant and anti-inflammatory properties. Methods A platelet aggregation model induced by arachidonic acid (AA), adenosine diphosphate (ADP) and thrombin (THR) was used to evaluate the antithrombotic effect of VAA in vitro and in vivo. Results In vitro, VAA significantly inhibited platelet aggregation induced by ADP and AA. And it could inhibit platelet aggregation induced by ADP in a dose-dependent manner. The results of in vivo experiments also showed that VAA (10, 30 and 100 mg/kg) decreased platelet aggregation induced by ADP and AA in a dose-dependent manner. In addition, VAA (100 mg/kg) could significantly reduce fibrinogen and increase prothrombin time, but had little effect on activated partial thromboplastin time and thrombin time. Conclusion VAA could inhibit platelet aggregation induced by ADP and AA, which provides reference for the development of new antiplatelet drugs.

Key words: vanillic acid, thrombotic diseases, platelet aggregation

CLC Number: